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Clonal evolution of a tumor ecosystem depends on different selection pressures that are
principally immune and treatment mediated. We integrate RNA-seq, DNA sequencing, TCR-
seq and SNP array data across multiple regions of liver cancer specimens to map
spatio-temporal interactions between cancer and immune cells. We investigate how these
interactions reflect intra-tumor heterogeneity (ITH) by correlating regional neo-epitope and
viral antigen burden with the regional adaptive immune response. Regional expression of
passenger mutations dominantly recruits adaptive responses as opposed to hepatitis B virus
and cancer-testis antigens. We detect different clonal expansion of the adaptive immune
system in distant regions of the same tumor. An ITH-based gene signature improves single-
biopsy patient survival predictions and an expression survey of 38,553 single cells across 7
regions of 2 patients further reveals heterogeneity in liver cancer. These data quantify
transcriptomic ITH and how the different components of the HCC ecosystem interact during
cancer evolution.
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Primary liver cancer is the fourth cause of cancer-relatedmortality worldwide. With more than 750,000 new casesannually (33,000 in the United States (US)), it has become
the fastest growing malignancy in the United States (US), both in
terms of incidence and mortality1. Hepatocellular carcinoma
(HCC) is the most frequent form of liver cancer and it generally
develops in the context of chronic liver disease due to viral
hepatitis B or C, alcohol abuse and non-alcoholic fatty liver dis-
ease. Hepatitis B virus (HBV) infection is the main cause of HCC
worldwide, and the World Health Organization estimates that
257 million people are living with HBV. Despite the clinical
efficacy of molecular therapies in HCC patients at advanced
stages1, the almost inevitable emergence of drug resistance stands
in the way of a definitive cure. The ability of cancer cells to adapt
to pharmacological pressures can be described in terms of tumor
evolution, and stems from the intrinsic diversity, or heterogeneity
of cancer2. Cancer heterogeneity defines the distinct genetic
alterations and phenotypes between cancer cells within the same
tumor nodule (i.e., intratumor heterogeneity or ITH) or between
different tumor nodules within the same patient. ITH can have
major clinical consequences, as falsely classifying subclonal
mutations as clonal drivers may misdirect treatment decisions.
This sampling bias can potentially impact decision-making when
using molecular information derived from a single tissue biopsy,
as recently described in lung cancer3.
Multiregional tumor sampling has helped to characterize ITH,
both at the phenotypic and genetic levels, in an attempt to
reconstruct phylogenetic and spatio-temporal relationships of
geographically distant tumor regions4. An emergent theme from
these studies is that the spatio-temporal dynamics of ITH are not
entirely captured by DNA somatic mutations alone3. Even though
tumors are complex ecosystems incorporating nontumoral cells,
few studies have addressed how the tumor microenvironment, in
particular the immune system, contributes to ITH. A recent study
integrated DNA sequencing data, gene expression, and T-cell
clonality from multiple tumor sites of ovarian tumors to report
heterogeneous cancer-immune interactions highly suggestive of
immunoediting5. Along these lines, another study found different
activation states of the immune system during the transition from
in situ to invasive breast cancer6, with intriguing evidence of co-
evolution of cancer and immune cells. These reports underscore
the importance of understanding the interactions between cancer
and immune cells within tumor ecosystems, especially consider-
ing the remarkable success of immune checkpoint inhibitors in
heterogeneous solid tumors7. In this context, HCC offers a
unique opportunity to determine the contribution of tumor and
viral antigens in immune activation, a feature relatively unex-
plored using immunogenomics.
Results from two phase 2 clinical trials using PD-1 inhibitors
suggest that a subgroup of HCC patients (~18%) significantly
benefit from immune checkpoint inhibition1. We hypothesize
that a better understanding of the interactions between HCC and
the immune system can help identify biomarkers of response to
these therapies. To investigate the natural history of these inter-
actions, we integrated data (i.e., RNA-seq, DNA targeted
sequencing, TCR sequencing, and DNA copy number changes)
from multiple regions of 14 HCC resection specimens, including
single-cell RNA-seq data from seven regions of two patients.
Leveraging our unique multiregional dataset, we used an immu-
nogenomics approach to find evidence of a tumor-driven adap-
tive immune response correlating with ITH. Our model suggests
that tumor neoantigens dominantly recruit tumor infiltrating
lymphocytes (TILs) compared to other sources of antigens (e.g.,
HBV, cancer testis antigens (CTAs)). Furthermore, we uncover
strong regional differences in transcriptional factor networks at
the single-cell level.
Results
Regional clonal immune responses fuel ITH in HCC. We
compiled a dataset of 71 multiregional samples from 14 HCC
patients, including 51 tumoral and 20 nontumoral adjacent
regions (median of 3.5 tumor and 1.5 nontumor regions per
patient, including a technical replicate for region A of patient 2
(P02)). All patients except P09 had single-nodule early stage HCC
(Barcelona Clinic Liver Cancer stage A)8 and were treated with
surgical resection without any prior therapy (Fig. 1a). Most
patients were male (64%, 9/14), with a median age of 63 years,
and a median tumor size of 65 mm. As expected, considering that
the underlying liver disease was predominantly due to HBV (50%,
7/14), the majority of patients did not have severe fibrosis in the
adjacent nontumoral liver (63% (7/11) as quantified using the
METAVIR score9 (Supplementary Table 1). Histological evalua-
tion of tumor grade and immune infiltrate demonstrated phe-
notypic ITH in 50% (7/14) of patients (Supplementary Fig. 1a, b).
Regional variations in tumor purity were confirmed using DNA
data from genotyping arrays. The regions with the lowest tumor
cell purity as determined with ASCAT (version 2.4)10 were the
ones with the highest immune infiltrate on histological exam-
ination (Fig. 1b).
To assess regional transcriptomic heterogeneity, we evaluated
major axes of variability of the gene expression data using
multidimensional scaling (MDS). As expected, there was a clear
separation between tumor and nontumor regions and further-
more, for most patients, all tumor regions tended to colocalize
(Fig. 1c). There were 5/12 (40%) patients (P02, P03, P04, P09, and
P11) with at least one region closer to those of another patient
than to the other regions of the same tumor. When we integrated
data of TIL burden, we found that most patients with outlier
regions had heterogeneous distribution of immune infiltrate as
per histological evaluation (P02, P03, P09, and P11). This
suggested that tumor-immune infiltrate could be a major
determinant of transcriptomic ITH and motivated us to study
the regional interactions between cancer and immune cells using
immunogenomics.
To better characterize the intensity and characteristics of
regional TIL burden in HCC, we first quantified the B and T cell
receptor (B/TCR) RNA-seq reads mapping to VDJ loci and
normalized by total library size in all samples. The nontargeted
and sparse nature of these data prevents a deep characterization
of the TIL receptor repertoire. Nevertheless, previous studies
confirmed the validity of RNA-seq data to infer immune
clonotypes and to provide a reasonable proxy of TCR diversity
in tumor samples11. We found that tumor regions classified as
having severe immune infiltrate on histology had significantly
more RNA-seq reads mapping to the VDJ loci than those
classified as having less immune infiltrate (P= 1.1e−10) (Fig. 2a).
We confirmed significant ITH in TIL burden in P02, P03, and
P06 with higher VDJ read count in regions H2.a and H2.e
compared to H2.b, H2.c, and H2.d, in region H3.a compared to
H3.b, and in H6.a compared to H6.b (Fig. 2b). These estimates
were confirmed with TCR sequencing for patients 3 and 6. This is
consistent with a recent study that reported ITH in HCC immune
infiltrate12.
We next sought to quantify the degree of T-cell clonality in the
different regions of the same tumor. We hypothesized that
differences in TIL burden across regions could be due to
differences in local immune clonal expansions. We conducted
TCR sequencing (ImmunoSeq) in multiple regions of P03 and
P06. Despite the fact that we did not find significant differences in
overall T cell clonality between the different regions of P03 and
P06, there were significant differences in the number of unique T-
cell expansions detected in the different regions of these patients
(Fig. 2c). Regions H3.a and H6.a had significantly more unique
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T-cell expansions than H3.b and H6.b, respectively. To better
understand the nature of the regional differences in TIL, we
examined the architecture of the TILs in P02, P03, and P06 using
immunofluorescence for T (CD3) and B (CD20) cell markers. We
detected tertiary lymphoid structures (TLS, confirmed with PNAd
staining for High-Endothelial Venules (Supplementary Fig. 2a))
in some of the regions of P02 and P03, but not in P06, where
T cells had a diffuse distribution intermingled with cancer cells
(Fig. 2d). TLS are transient ectopic lymphoid organizations that
develop in nonlymphoid tissues functioning as important sites for
the initiation and/or maintenance of immune responses. In HCC,
the presence of intratumoral TLS correlates with a lower risk of
tumor recurrence13. Interestingly, P02 had regional differences in
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Fig. 1 Summary of sampling and tumor purity data. a Geographic distribution of the multiregional sampling (H: HCC sample; N: Nontumoral adjacent;
Orange: Samples bulk sequenced; Green: Samples single-cell sequenced). b Regional tumor cell purity determined with ASCAT. c PCA of tumor and
nontumor regions of all patients included in RNA-seq (Circles: HCC; Triangles: Adjacent nontumor).
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pattern in H2.a, whereas H2.e predominantly had TLS alone.
This, combined with our previous findings of low TIL burden in
H2.e compared to H2.a, prompted us to hypothesize that TLS
density is a proxy for the timing of the interaction between cancer
and immune cells. To test this, we used (1) quantification of
relative fractions of immune cell subsets using data deconvolution
methods14, and (2) T-cell cytotoxicity as measured by the
Immune Cytolytic Activity Index15. Compared to H2.e, region
H2.a had a higher proportion of memory B-cells, CD8-T cells,
CD4 memory cells, and macrophages, suggestive of a more
mature immune response (Supplementary Fig. 2b). Additionally,
T-cell cytotoxicity was higher in H2.a compared to H2.e
(Supplementary Fig. 2c). These data prompted us to further
examine the regional interface between cancer and immune cells
and its contribution to transcriptomic ITH.
Predicted neoepitope immunogenicity is spatially variable. To
study the interactions between cancer and immune cells, we first
computed the predicted immunogenicity of tumor neoepitopes
across the different regions of all tumors. Despite these predic-
tions being suboptimal compared to directly identifying presented
epitopes via mass spectroscopy16, there is evidence suggesting
that in silico predicted binding affinities form useful priors
for immunologic reactivity17. First, we called expressed somatic
mutations using RNA-seq data. Despite being inferior to DNA
mutation calling, numerous reports demonstrate the usefulness of
RNA-seq-based mutation calling18. There was significant het-
erogeneity in the distribution of expressed somatic mutations
across regions, with an average per patient ranging from 70 (P06)
to 225 (P03) (Supplementary Fig. 3a, Supplementary Data File 1).
However, we found a clear patient-specific clustering of somatic
mutations (Supplementary Fig. 3b). To determine if this regional
heterogeneity in expressed mutations was also affecting known
HCC drivers, we conducted targeted DNA deep sequencing of the
58 genes most frequently mutated in HCC. We confirmed a
clonal distribution of known drivers, such as TERT promoter,
CTNNB1, and TP53 (Supplementary Fig. 3c, Supplementary
Table 2), with only one tumor region (H4.a) depicting a subclonal
mutation of CTNNB119. Using DNA Sanger sequencing, we
validated 11 expressed mutations predicted as damaging (Sup-
plementary Table 3).
We then estimated in silico regional differences in neoepitope
distribution by assessing putative immunogenicity of the
expressed mutations. We first allelotyped the samples for all six
HLA class I molecules. HLA-I alleles were stably expressed across
all regions except for P05 (Supplementary Fig. 4, Supplementary
Data File 2). We combined the expressed HLA-I alleles and
mutations (i.e., predicted neoepitopes) using the well-established
netMHC algorithm20 to estimate the binding affinity of each
Absent Mild Moderate Severe














































Number of B/T cell clones









































































H6.a TCR frequency (%)







































































Fig. 2 Immunogenomic view of regional cancer-immune interactions in HCC and immune infiltrates. a Number of RNA-seq reads mapping to VDJ loci
grouped by pathological immune infiltrate assessment (ANOVA, error bars= SE, N= 38 samples. For each boxplot, the centre line represents the median.
Upper and lower limits of each box represent the 75th and 25th percentiles, respectively. The whiskers represent the lowest data point still within 1.5× box
size of the lower quartile and the highest data point still within 1.5× box size of the upper quartile). b Number of RNA-seq reads mapping to VDJ as a
function of the number of unique reassembled CDR3 sequences (i.e., number of unique immune clones). c Scatter plot of TCR rearrangement frequencies
between tumoral regions of patient 3 and 6. TCR rearrangements found at significantly higher frequencies in region H3.a/H6.a than H3.b/H6.b are filled
in blue. TCR rearrangements found at significantly higher frequencies in region H3.b/H6.b than H3.a/H6.a are filled in red. d Paired H&E and
immunofluorescence of CD3 and CD20 in high TIL burden regions of P02 and P06 (CD3: Red; CD20: Green; black bar 100 µm; white bar 50 µm, N= 3
independent experiments). Source data are provided as a Source Data file.
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HLA/neo-peptide combination across tumor regions. This
binding affinity quantifies the likelihood of a given neoepitope
being presented on the surface of a tumor cell and potentially
being recognized by a T cell. While a critical binding affinity of a
neoepitope to a given HLA-I allele is required for actual
immunogenicity, it is only suggestive compared to directly
identifying presented epitopes via mass spectroscopy16. However,
mounting evidence suggests in silico predicted binding affinities
are useful for vaccine design and disease diagnostics21.
We predicted between 41 and 466 HLA/neoepitope combina-
tions per tumor region (Supplementary Data File 2). We
conducted multiregional comparison of the distribution of
predicted neoepitope binding affinities. This overcomes the
difficulty of comparing distinct HLA alleles from different
patients using data from single biopsies. In P02, H2.e is
significantly more immunogenic than H2.a (P < 1e−8), followed
by regions H2.d, H2.c, and H2.b (P= 2e−4, P= 5e−4, P= 1e−3,
respectively, Fig. 3a). A similar heterogeneous pattern holds in
P09, P04, P03, and P05 (Supplementary Fig. 5). In contrast, all
regions of P10 are predicted to be similarly immunogenic,
consistent with those of P08, P06, P01, P11, and P12 (Fig. 3a,
Supplementary Fig. 5). Expressed clonal mutations, as defined by
a variant allele fraction (VAF) higher than 0.3 tend to emit fewer
immunogenic neoepitopes than subclonal mutations (Fig. 3b).
This was confirmed using whole-exome sequencing (WES) data
in P10. In all the regions analyzed in this patient, the predicted
immunogenicity of subclonal mutations was significantly higher
than for clonal mutations (Supplementary Fig. 6). Defining
passenger mutations by their expression in only some regions of
the same tumor nodule, i.e. branch mutations, we also observed a
significant increase in predicted immunogenicity compared to
mutations present in all regions (trunk mutations), (P= .02).
These included the candidate HCC driver genes TP53, CTNNB1,
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Fig. 3 Neoantigen binding affinity. a 2D density of log-scaled peptide binding affinity as a function of the VAF of somatic mutations across regions of P10
and P02. Dotted line depicts 50% inhibitory concentration (IC50)= 500 nM (lower IC50 means stronger binding and higher immunogenicity, HLA-I class
A: circle; HLA-I class B: Triangle; HLA-I class C: square). b Empirical cumulative density plot of log-scaled binding affinity distribution for neoantigens
according to VAF of expressed mutations. Kolmogorov-Smirnov test with one-sided alternative hypothesis. p-value is for rejecting the null in favor of the
alternative. c Log R Ratio (LRR) mean as a function of DNA segmentation for each tumoral region. d Y-axis depicts one-sided Kolmogorov-Smirnov test p-
value for regional sample pairs of neoantigen binding affinity profiles, i.e., a quantification of the relative shift of putative immunogenicity between paired
tumor regions. X-axis depicts the difference in the number of RNA-seq reads mapped to the VDJ locus between the first and second region of each pair, i.e.,
the regional differences in adaptive immune burden. Sample pairs are colored based on tumor grade. Source data are provided as a Source Data file.
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Indeed, all three driver mutations give rise to neoepitope
distributions with average binding affinity greater than 1000
nM. The threshold of 500 nM is used to define high binding
affinity and select peptides as candidates for cancer vaccines22.
This is consistent with the expectation that early somatic driver
mutations should be immune-evasive.
In the patient with the highest TIL heterogeneity (P02), we
found an association between changes in regional neoepitope
immunogenicity and TIL burden. Region H2.e has the most
putatively immunogenic neoepitopes while H2.a has the least, and
yet H2.a has the greatest TIL burden in that patient. Given that
tumor grade in H2.a is poorly differentiated, followed by H2.e
(i.e., moderately differentiated) and the other regions (i.e., well
differentiated), it is suggestive that the adaptive immune response
in H2.a has edited the tumor to be much less immunogenic,
termed negative selection. P02, along with P06 (highest TIL
burden overall), both had regions with significantly higher DNA
segmentations as shown by CNV analysis (Fig. 3c). This reflects
intrinsic genetic differences in tumor cells in these regions which,
in addition to TIL burden, likely contribute to the transcriptomic
heterogeneity we find in our RNA-seq data (Fig. 1c). Conversely,
in the patient with the lowest TIL burden, P10, we find minor
variations among the regional neoepitope predicted immuno-
genicity (Fig. 3d). In addition, we find that key immune
checkpoint genes (e.g., CTLA4, PDCD1, CD274) are upregulated
and correlated with TIL burden, indicative of an inhibitory
response toward T-cell activation (Supplementary Fig. 7).
Limited contribution of HBV and CTAs to TIL recruitment. In
patients with HBV-related HCC, the relative contribution of
tumor neoantigens and HBV antigens to TIL recruitment is
unknown. In principle, TILs should respond to any nonself
peptides, regardless of their tumoral or viral origin. To elucidate
the role of HBV in TIL recruitment, we first evaluated expression
of HBV transcripts assembled from RNA-seq reads not mapping
to the human genome, and ultimately used them to predict
immunogenicity of HBV antigens. These antigens can arise from
HBV covalently closed circular DNA or HBV insertions in DNA
malignant hepatocytes. We found patients with strong variability
in HBV expression between tumor and adjacent nontumoral
tissue (Fig. 4a), a feature previously reported in HBV-related
HCC23. Furthermore, we observed variation in HBV expression
in different tumoral regions of patients P02, P04, and P10,
including some regions showing no expression of HBV tran-
scripts (e.g., region H2.a of P02). This suggests differential
selection pressure on infected tumor clones. We also found evi-
dence of HBV DNA integrations, including the previously
described FN1 (Supplementary Table 4) integration. Importantly,
when compared to tumoral neoepitopes from any given region,
the predicted binding affinity of HBV peptides is shifted towards
lower binding affinity than mutation-derived neoepitopes (P=
2.1e−8, P= 1.9e−4 for P02 and P10, respectively; Fig. 4b). This
suggests that in HBV driven HCC tumors, neoepitopes dominate
HBV epitopes in their recruitment of TILs. Though such a sug-
gestion awaits confirmation via mass spectroscopy, we also note
the reported impact of HCC-cell differentiation in HBV replica-
tion24, which could further decrease the pool of HBV epitopes
competing with tumor neoantigens.
Next, we evaluated self-antigens as another source for TIL
recruitment, as they are known constituents of the cancer
antigenome25. CTAs are among the better-studied tumor
antigens26, they are frequently re-expressed in HCC, and they
have been evaluated as candidate cancer vaccines. We did not
compute their putative immunogenicity because they are self-
proteins. When considering gene expression of the whole gene
family26, Gene Set Enrichment Analysis of CTAs showed a
heterogeneous enrichment across our multiregional dataset,
mainly for patients P01, P04, P09, and P12. However, CTA
enrichment score was not correlated with TIL infiltrate either by
histological assessment or VDJ read count. As in previous reports,
our data suggest that CTA expression alone seems insufficient to
elicit an intratumoral immune response27 (Fig. 4c).
ITH gene expression signatures predict outcomes in HCC.
Given the high scale of ITH we observed from the immune,
neoantigen, and HBV antigen analysis enabled by multiregional
sampling, we next sought to characterize the gene expression
landscape of ITH. We hypothesized that intratumoral differential
gene expression would capture important clonal and immune
evolution information in HCC. If true, this signal should have
survival impact in a cohort of single-biopsy HCC. To test this,
and also directly address their clinical relevance, we used our
multiregional gene expression dataset for feature selection and
leveraged the TCGA-HCC Cohort28 as a testing set for the sur-
vival correlations. We first assessed known readouts of tumor
clonality in the TCGA-HCC Cohort by calling DNA-based
somatic mutations for each tumor within the TCGA-HCC
Cohort with whole-exome sequencing data (WES) available
(N= 188). DNA-based tumor clonality outperformed number of
DNA mutations to predict survival in TCGA-HCC, suggesting
that DNA mutation number might be a suboptimal proxy of ITH
in HCC (Fig. 5a, b) and underscoring the possible role of ITH in
survival prediction.
We performed all possible pairwise regional differential
expression comparisons between tumor regions in patients with
at least three regions sampled. These comparisons can be
interpreted as principal spatial axes for tumor gene expression,
highlighting the rich dynamics that underlie ITH. Using nested-
cross-validation (see Methods, Supplementary Fig. 8a, b) to
simultaneously control for overfitting and hyperparameter
adjustment, we iteratively learned optimal combinations of
regional differential expression signatures and computed the
Integrated Brier Score on holdout test-sets to evaluate their
prognostic power on the TCGA-HCC dataset. The IBS score
measures the goodness of prediction for censored data, which
essentially quantifies the accuracy of prognostic predictions in
survival analysis with Cox regression29. The set of genes
differentially expressed between region H2.a and regions H2.b-
c-d-e of patient 2 had the lowest Integrated Brier Score (i.e.,
prediction error) for survival in the TCGA-HCC dataset. We used
a procedure of variance ranking30 to select the minimum number
of genes required to retain the predictive power of the P02
gene set. The resulting ITH signature (363 genes, Supplementary
Data File 3) was detected in 38% (139/359) of patients in the
TCGA-HCC dataset and it was associated with significantly worse
survival (N= 359, Fig. 5c). Reasoning that our ITH signature
from P02 rivals current single-biopsy prognostic HCC signatures
(e.g., G3, 5-gene or EpCAM signatures31), we compared their
prognostic accuracy by comparing their Integrated Brier Score as
a function of survival time (Fig. 5d). The ITH signature has the
lowest prediction error compared to any of the best single-biopsy
based predictors and the least optimistic discrimination index
across an additional repeated cross-validation analysis (P < 0.03,
Supplementary Fig. 8c). The ITH signature was also correlated
with early tumor recurrence in the Heptromic Cohort (Supple-
mentary Fig. 8d), as well as with higher levels of the poor
prognostic biomarker alpha-fetoprotein (Supplementary Fig. 8d).
In this dataset, the performance of the ITH signature was similar
to the other single-biopsy prognostic signatures (Supplementary
Fig. 8e).
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Single-cell RNA-seq reveals regulatory ITH. Our bulk sequen-
cing data suggest a strong impact of cell-type admixture in ITH.
Thus, to explicitly examine the HCC ecosystem at the cell-type
and gene regulatory network level, we conducted whole lysate
(i.e., no previous cell enrichment) single-cell RNA-seq from
geographically distant regions in 2 HCC patients. Overall, we
profiled 21,143 and 17,410 cells from 3 and 4 tumoral regions in
P13 and P14, respectively. Computing the t-SNE plot and labeling
cells based on the region they were derived shows that most
clusters are contributed by cells obtained from all three regions in
P13 (Fig. 6a). Conversely, the t-SNE plot in P14 is more
regionally clustered, with cell clusters mainly contributed by
distinct single tumor regions. As expected, the majority of cells
detected in both patients had hepatocyte lineage. Differentially
expressed genes across clusters in P13 (Fig. 6b, Supplementary
Data File 4) revealed an ecosystem of cells including hepatocytes
(ALB, FGG), cancer-associated fibroblasts (ACTA2, TAGL),
endothelial (KDR, VWF), myeloid-derived (HLA-DQB1, CD68),
and sporadic B-cells (IGJ, CD79A), which is consistent with the
lack of immune infiltrate on histological examination in this
patient (Supplementary Fig. 1b). Using these same markers, we
recapitulated identical cell lineages in P14. However, we did
detect another lineage not present in P13, characterized by the
overexpression of GNLY, NKG7, and CCL5 (Supplementary
Fig. 9). GNLY is a cytolytic protein produced by activated T and
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Fig. 4 HBV antigen binding affinity and CTA immunogenicity. a Expression distribution of HBV for adjacent nontumoral and tumoral regions across
patients (HCC: Red; Adjacent nontumoral: Green, error bars= SE, N= 44 samples. For each boxplot, the centre line represents the median. Upper and
lower limits of each box represent the 75th and 25th percentiles, respectively. The whiskers represent the lowest data point still within 1.5× box size of the
lower quartile and the highest data point still within 1.5× box size of the upper quartile). b Empirical cumulative density plot of log-scaled binding affinity
distribution across regions for both HBV and tumor neoepitopes. Kolmogorov-Smirnov test with one-sided alternative hypothesis. p-value is for rejecting
the null in favor of the alternative. c Correlation plot of CTA enrichment score and RNA-seq reads mapped to the VDJ locus across regions. Source data are
provided as a Source Data file.
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Co-expression of CD3 and GNLY in these cells using immuno-
fluorescence (Fig. 6c), predominantly in region H14.c, confirmed
their cytotoxic phenotype. To test the hypothesis that regional
variance of HCC-cell expression in P13 is lower than in P14, we
first selected HCC cells and labeled them by their enrichment in
well-known HCC molecular classes33. We found that while most
HCC cells in P13 belong to the less aggressive S3 class, in P14
there is a strong representation of all three molecular subclasses,
as visually summarized in a topographic data analysis of the
expression data (Fig. 7a). We cannot rule out that any of the other
cells of the tumor microenvironment detected in these patients
(e.g., myeloid-derived, CAFs) could also drive ITH in HCC.
Next, we sought to quantify the regional transcriptional states
of HCC cells by inferring regional coexpression networks. The
transcriptional state of a cell depends on the underlying gene
regulatory network (GRN) resulting from upstream transcription
factor (TF) regulation. Technical and biological variance in
single-cell expression data (e.g. drop-out noise) typically hampers
gene expression network analysis, but recently cis-regulatory
sequence motif analysis has allowed scoring each cell by GRN
activity34. We leveraged these techniques to score GRN activity
and derive HCC-cell states across the different regions of the
same tumor nodule. Focusing only on HCC cells, we quantified
the activity of regional HCC GRNs and clustered cells based on
similar activation patterns (Fig. 7b). We found that while key
regulating TFs were turned on in all regions for each of the
patients (FOSB, JUNB in P14; HOXD9, JUNB in P13), there was
a remarkably high degree of regionality in TF activation patterns
even after regressing out regional biases (e.g., cell yield, number of
unique molecular identifiers, Supplementary Data File 5). For
example, in the poorly differentiated region H14.a we found a
very distinct GRN activation pattern of pluripotency signaling
orchestrated by the Yamanaka factor OCT435, as well as an
overall enrichment in NOTCH signaling compared to any other
region of P14 (Reactome, FDR= 0.05). Similarly, uniquely within
H13.a we found consistent activation of cell states enriched in the
ETS binding domain, namely in the TEL (e.g., ETV7) and ESE
(e.g., ELF3) subfamilies of the general ETS transcription factor
family, while in region H13.c cell states were dominated by RXRA
and MYCN TF activation. Altogether, these data reveal significant
heterogeneity in TF activation status across distant regions within
the same tumor nodule.
Discussion
Using multiregional omics data from 71 samples (N= 14
patients) we have unraveled key readouts of ITH in HCC. We
detected ITH in 30–40% of treatment-naive HCC encompassing
neoepitope burden, TIL burden and clonality, HBV expression
and regional gene expression profiles. A deeper characterization
of HCC-cell specific ITH using single-cell RNA-sequencing,
reveals substantial regulatory heterogeneity. Our finding of sig-
nificant regional differences in the magnitude of immune infil-
trate in HCC confirms previous reports12. Moreover, we derived
gene expression signatures reflecting intratumoral expression
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Fig. 5 Survival analyses of ITH models in TCGA-HCC. a Kaplan-Meier curves with HCC DNA mutations and b DNA-based clonality estimates. c Kaplan-
Meier curve for overall survival in the TCGA dataset after patients are classified based on the ITH signature. d Prediction error curves of competing
parametric Cox proportional hazard models depicting time dependent Brier score for models built from principal components of the G3, EpCAM, 5-gene,
and ITH signatures. Survival analysis was done using the Kaplan-Meier (log-rank) test.
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and immune infiltration and found that they outperform single-
biopsy derived signatures in predicting survival in the TCGA-
HCC cohort. Our observations of different regional immune
clonal expansions, and bias towards passenger mutation driven
neoepitope production, suggest the complexity of the evolving
tumor-immune interactions may contribute to the emergence of
ITH. Even though we confirm the presence of significant regional
chromosomal instability previously reported in other tumor
types3, this information alone does not completely recapitulate
the full scale of molecular ITH in our HCC samples. Simulta-
neously measuring TIL burden and clonality, regional neoepitope
variance, and potential viral cofactor signals using RNA-seq data
significantly increases the scope and value of bulk multiregional
data in assessing clinically relevant ITH. Our immunogenomic
regional data indicate that passenger mutations potentially con-
tribute more to TIL recruitment than driver mutations.
However, our data also imply that the average MHC-I-binding
affinity of tumor neoantigens exceeds that of HBV on a per-
antigen basis, suggesting that TIL recruitment is primarily tumor
induced. Indeed, we also observe a relative lack of correlation
between TIL burden and CTAs/HBV expression. Looking at the
actual architecture of the TIL response, it might be plausible to
define a chronology of key stages of the tumor-immune inter-
action, namely negative selection, via the formation (early) and
dissolution (late) of TLS. We found hot and cold patterns of
regional TIL burden5. The cold pattern, epitomized by P10,
includes virtually zero TIL. This minimal immune selection
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Fig. 6 HCC ecosystem and regional transcriptomic heterogeneity on single-cell RNA-seq. a t-SNE plots of single-cell clusters colored by tumor region
(H13.a: Green; H13.b: Yellow; H13.c: Pink) and b affiliation to cell lineage by gene expression. c Immunofluorescence staining for GNLY (red) and CD3
(green) in P14. Scale bar is 20 μm long in merge overview panels and 10 μm for all other panels. N= 3 independent experiments. Source data are provided
as a Source Data file.
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evolution and resource/viral-induced constraints. P10 expresses
both clonal TP53 and CTNNB1 mutations, which have been
proposed as mechanisms of immune exclusion in different
tumors, including HCC36. A similar pattern is also seen in other
patients with either CTNNB1 or TP53 mutations. The hot pattern
is exemplified by P02 and P06. In these tumors, which lack
TP53 or CTNNB1 mutations, we observe a regional adaptive
immune response, suggestively associated with tumor cell de-
differentiation and increased chromosomal instability. Along
these lines, a recent study of TIL in HCC confirms intratumor T-
cell clonal expansion at the single-cell level and reveals a highly
complex T-cell ecosystem37.
Our survival analysis reveals that regional transcriptional het-
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Fig. 7 Regulatory network heterogeneity at the single-cell level. a Geographic distribution of the multiregional sampling for single-cell RNA-seq.
Topology data analysis of HCC-cell population across regions, as visualized with Ayasdi Platform74. Cells are labeled based on tumor region and molecular
subclass. Each dot represents a node, the size of which corresponds to the number of cells that were clustered to form that node. Lines or edges between
nodes indicate they have cells in common. b Circular hierarchical clustering of HCC cells based on the activation status of TF derived from regulatory
networks using SCENIC34 (H13.a: Green; H13.b: Yellow; H13.c: Pink). Source data are provided as a Source Data file.
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survival signals in a large cohort of single-biopsy HCCs. Indeed,
our ITH signature, derived from the intratumor differential gene
expression of P02, retains independent prognostic value com-
pared to other well-known HCC survival predictors such as the
G3 signature38. We speculate on the broader implications of a
single patient tumor evolution trajectory capturing survival sig-
nals in a single-biopsy cohort such as the TCGA. Our ITH sig-
nature from P02 includes tumor states spanning from immune
cold and well-differentiated tumor regions (regions B, C, and D)
to poorly differentiated, weakly immunogenic and immune hot
regions (region A). These data suggest that the intratumoral
transcriptomic differences in P02 recapitulate the different stages
of tumor evolution found in a large cohort of HCC patients
across a spectrum of different clinical stages and somatic muta-
tion burden.
At the single-cell level, we examined the substrate of molecular
ITH beyond cataloging the regional variance of cell-type admix-
ture, and quantified gene regulatory heterogeneity of HCC cells.
Broadly, P13 resembled the cold P10 while P14 had one region
with only moderate immune infiltrate (H14.d), preventing a
single-cell view of the hot pattern we observed in the bulk data.
The single-cell data did nevertheless identify important basic
differences between the two patients, with HCC cells in all regions
of P13 mostly belonging to one molecular class while belonging to
many classes in P14. At the gene regulatory level, we observe
more profound differences in TF signaling among the regions of
P13 and P14, including pluripotency signaling in poorly differ-
entiated regions. It is remarkable that TF activation state in HCC
cells can largely recapitulate what tumoral region they came from,
indicating that downstream expression reprogramming of clonal
evolution is highly dynamic.
Despite the relatively low number of patients included in our
study, this is the largest and most comprehensive analysis of
transcriptomic ITH in HCC reported so far. Other limitations of
our analysis include the under-sampled TIL representation and
the estimates for RNA-seq variant calling, which are contentious
in the context of varying tumor purity. Despite our regional
somatic mutation overlap, and targeted DNA mutation validation
suggest reasonable coverage levels, our sensitivity is probably low.
While whole-exome sequencing data in one of our patients
confirmed our main conclusions, the difficult question of how to
threshold expressed mutations would remain. Another possible
limitation relates to the classic question of the accuracy of in silico
predictions of neoantigen binding affinity in estimating immune
reactivity. For example, a detailed characterization of the tumor-
derived ligandome in melanoma using mass spectrometry ques-
tioned the ability of these predictions to identify highly immu-
nogenic neoepitopes, particularly for the top 10 predicted
binders16. Nonetheless, in silico prediction of binding affinity was
successfully used in two phase I clinical trials testing personalized
vaccination in patients with melanoma17,39. Considering that our
study is not aiming to identify top binders but rather characterize
broad relative shifts in the predicted binding profile within
individual tumors, we believe that these potential discrepancies
do not have a major impact on our results. Finally, we
acknowledge that including MHC class II epitopes into these
regional analyses may offer new insights by more fully char-
acterizing regionally varying adaptive immune response (though
we note the relative lower predictive accuracy in binding affinity
compared to HLA-I39). Experimental studies will be required to
validate our results of neoantigen and viral immunogenicity and
their impact in immune recruitment and cancer clonal compo-
sition in HCC.
In conclusion, this study sheds further light on the underlying
molecular features of ITH in HCC including the unexpectedly
large scale of regulatory heterogeneity of HCC cells. The
relevance of quantifying regional differences in cancer-immune
interactions is only highlighted by the ongoing pan-cancer
revolution in immunotherapy, providing new directions to
treatment biomarker discovery.
Methods
Human samples and histological evaluation. All patients were enrolled at Icahn
School of Medicine at Mount Sinai (ISMMS) and provided informed consent for
tissue biobanking. Study was approved by the Mount Sinai IRB (IRB# HS-14-
01011) and samples were provided by the ISMMS Tissue Biorepository (IRB# HS-
10-00135). All patients had early stage hepatocellular carcinoma (HCC) as per
EASL guidelines40, and were treatment-naïve prior to resection. Frozen tissue
samples were collected allowing for at least 1 cm of distance between each other.
Samples were selected from areas without macroscopic evidence of necrosis or
hemorrhage. For morphological analysis, sections were cut (5 µm thick), stained
with hematoxylin and eosin (H&E), and evaluated by an expert liver pathologist.
The histological features evaluated included tumor grade by the WHO (i.e., well,
moderately and poorly differentiated), a semi-quantitative evaluation of immune
cell infiltrate and steatosis (absent, mild, moderate, and severe), and enumeration
of mitotic figures per high-power field (Supplementary Table 1). Degree of fibrosis
in the adjacent nontumoral liver was assessed using the METAVIR scoring
system9.
Nucleic acid extraction and DNA sequencing. DNA and RNA were extracted
using the DNeasy blood and tissue kit and RNeasy mini kit (Qiagen), respectively.
RNA quality was assessed with the RNA Integrity Number (RIN) as provided by
2100 Bioanalyzer (median RIN for samples submitted to RNA-seq was 9). The
purified DNA was run on a 2100 Bioanalyzer Instrument (Agilent) for size esti-
mation, and its concentration was measured by fluorometric quantitation using
Qubit (ThermoFisher). All targeted DNA sequencing identified somatic mutations
predicted as damaging by Poylphen or SIFT and were above 5% VAF were sub-
jected to Sanger sequencing for validation. We used the following criteria for
validation of RNA-seq mutation calls with Sanger sequencing: (1) Somatic muta-
tions; (2) predicted as damaging by Polyphen or SIFT, (3) Read depth greater than
10; (4) VAF greater than 40%; (5) recurrent among multiple tumor regions. Pri-
mers used for Sanger sequencing are listed in Supplementary Table 5. For Sanger
sequencing, each PCR product was assessed on a 1.5% agarose gel, sequenced in
both directions using BigDye Terminator Cycle-Sequencing Kit (Macrogen) and
loaded on an ABI PRISM 3730xl DNA analyzer. Sequences were analyzed using the
Applied Biosystems’ sequencing analysis software with the KB base-caller. Targeted
next generation DNA sequencing was performed for all exons of a panel of 58
genes frequently mutated HCC genes (Supplementary Table 6). Indexed Illumina
NGS libraries were prepared from tumor and nontumor adjacent tissue (P01-5) or
peripheral blood mononuclear cells when available (P06-10). Sequence captures
were carried out using the Biotinylated custom baits of Agilent SureSelect oligo
pool (Agilent Cat #5190-4808). DNA targeted sequencing data from P6-P10 were
recently reported, including detailed methodology of library preparation, sequen-
cing, and data analysis41. Whole-exome sequencing analysis of patient 10 was
performed on 125 bp paired end reads using an Illumina Nextseq 500 platform
(Nextseq High output flow cell, 300 cycle baits). Libraries were constructed using
the SureSelect XT low input with V7 baits (Protocol Version B1) following the
standard protocol. WES data processing was performed using a custom nextflow
pipeline that is available on GitHub (https://github.com/losiclab/exoseq). Raw
reads were trimmed and aligned to the hg38 reference genome using trim-
galore42,43, bwa mem44, and samtools45, respectively. Duplicate reads were then
marked using picard MarkDuplicates, and bam quality scores were recalibrated for
known technical bias using GATK4 base recalibration46. Quality control metrics
were compiled using fastqc2 for raw reads and picard CollectMultiMetrics for
aligned reads. Somatic variants were called using Mutect246–48 in WES tumor-
normal matched data, with the intervals parameter set to all coding regions, and
with 1000 genomes as the germline resource. Variants were filtered for quality
control using GATK FilterMutectCalls with default parameters. Only variants with
a VAF > 5% were retained for further analysis. Variants were annotated with
Annovar (version 2019Apr09).
DNA copy number analysis. Hybridizations were performed at the Genomics
Core Facility of the ISMMS using the high-resolution HumanOmni2.5-8 Beadchip
genotyping arrays (Illumina). Adjacent nontumoral tissue or peripheral mono-
nuclear blood cells (for P07, since no adjacent nontumoral tissue was available for
this patient) were used as controls. Copy number variation was studied at the level
of allele-specific variation (ASCAT version 2.110) and at whole copy number
variation (Circular Binary Segmentation, CBS, relying exclusively on log R Ratios of
cases vs. controls). We used ASCAT to dissect the allele-specific copy number
alterations, while simultaneously estimating and adjusting for both tumor ploidy
and non-aberrant cell admixture. To analyze focal events of the copy number
alteration (CNA) profiles, we used as input the average Log R Ratios per segment
obtained from CBS.
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Immunofluorescence staining. Frozen histological sections were immersed in
pre-cooled methanol (−20 °C) for 15 min. Blocking was performed for 1 h at room
temperature with a solution composed of 1X TBS, 10% BSA and 0.3% Triton-X.
Sections were incubated overnight (4 °C) with primary antibodies against CD-3
(dilution 1:50, DAKO A0452), CD-20 (dilution 1:200, DAKO M0755), granulysin
(dilution 1:100, Santa Cruz sc-271119), and PNAD (dilution 1:200, BD Biosciences
553863). AlexaFluor® 488 (dilution 1:200, Invitrogen A21121 and A21212),
AlexaFluor® 546 (dilution 1:200, Invitrogen A11030), and AlexaFluor® 594 (dilu-
tion 1:200, Invitrogen A11037) secondary fluorescent antibodies were applied for 1
h at room temperature. Nuclei were labeled with DAPI (dilution 1:1000, Invitrogen
D1306) and slides were mounted with Fluoromount-G® (SouthernBiotech).
Stained slides were evaluated using a Nikon Eclipse NI microscope and a Zeiss
Axio Observer 7 with appropriate filters.
RNA sequencing. RNA-seq was conducted on poly-A enriched RNA, 100 bp
single reads using an Illumina HiSeq2500 instrument. Among the tumor regions
analyzed with RNA-seq, we also included a technical replicate of region A of P02
(i.e., H2.a). Libraries were constructed using the TruSeq RNA Library Prep Kit v2.
Raw sequencing reads were mapped to the GRCh38 reference genome (USCS)
using STAR (version 2.4.2g1)49. Aligned reads were mapped to GRCh38 genetic
features using featureCounts from the subRead package50 with default settings,
with a median coverage of 30 million mapped reads per region.
HLA typing and expression. Raw sequencing reads were re-mapped to all known
HLA-I alleles using a 4-step approach. First, a low-stringency mapping was per-
formed using razers3 to identify HLA-matching reads51. If there were more than
10,000 such HLA reads, they were next randomly down sampled to produce a more
manageable, smaller output file (with a maximum of 10,000 reads). For step three,
Optitype (version 1.0)52 was used on this low-stringency, potentially down-
sampled HLA-specific, razers3 output to consensus call the HLA alleles. Briefly,
this method finds an allele combination that maximizes the number of reads they
explain. Finally, the overlap of reads mapping to distinct alleles was quantified by
assigning fractions of read support to each allele using a custom script that operates
only on the high-stringency mapping output of Optitype.
RNA variant calling and putative neoantigen calling. Mapped RNA-seq reads
were subject to splitting, trimming, local indel realignment, and base-score reca-
libration pre-processing with the IndelRealigner and TableRecalibration tools from
GATK53 under the GATK Best Practices for RNA-seq paradigm. Mutect (version
2.0)48 was then used to compute the regional somatic mutation burden in the
following fashion. For each patient, all reads from adjacent nontumoral regions
were combined to form an effective normal against which tumor regions were
tested for somatic mutations. Somatic calls from mutect with fewer than 10 sup-
porting variant reads were not considered. The technical replicate for P02, region
A, was removed due to a failure in the GATK base quality recalibration model. To
predict neoantigen and associated epitope burden, we used Topiary (Rubinsteyn
and Nathanson, https://github.com/hammerlab/topiary) to call mutation-derived
cancer T-cell epitopes from somatic variants, tumor RNA expression data, and
patient class I HLA type. This tool matches mutations with gene annotations, filters
out non-protein coding changes, and finally creates a window around amino acid
changes, which is then fed into NetMHCCons for each patient HLA allele across
tiles of 9-12 amino-acid in length20. Given that HLA-I processes neoantigens by
degradation to non-conformational 8-11 amino-acid residues, we only included
those sizes and excluded neoepitopes with mutations obscured to T-cells within
HLA-I binding pockets. In the case of frameshift mutations, in principle this
window starts from the mutation minus the length of the peptide up to the first
stop codon. To compare pairs of empirical cumulative density (ECDF) of binding
affinities between regional tumor neoantigens within a patient, we used a one-sided
Kolmogorov-Smirnov test. The alternative hypothesis is that one ECDF is shifted
to lower binding affinity compared to the other. Since the high binding affinity
modes of the distribution are essentially noise from the netMHCCons predictions,
the one-sided test is mainly sensitive to differences in the low binding affinity tail,
which contains putative neoantigens. A low p-value indicates that one distribution
is shifted towards higher binding affinity (i.e., higher putative immunogenicity)
compared to the other.
T/B cell receptor sequencing and inference. DNA: T cell receptor beta chain
CDR3 regions were sequenced by ImmunoSeq (Adaptive Biotechnologies), with
primers annealing to V and J segments, resulting in amplification of rearranged
VDJ segments from each cell. Clonality and richness values were obtained through
the ImmunoSeq Analyzer software. Differential abundance analysis was assessed
using Fisher’s exact test and a beta-binomial method to increase stringency, as
previously described54,55, to identify clones that were significantly expanded in
different regions of the same tumor nodule.
RNA: Mapped RNA-sequencing reads were used to allelotype (MHC class-I
loci) each patient, estimate the putative TIL burden per patient by profiling TCR
and BCR sequences with MiXCR56, and normalizing by patient library size.
Generally the strategy for this class of algorithms can be summarized in several key
steps, namely stringent pre-processing (including using frequency-based
corrections for PCR artifacts and other sequencing errors), basic corrections for
allelic differences between patients, and identification of deletions and insertions
prior to alignment to receptor sequence without intronic sequence for the case of
RNA-seq reads. In detail, after pre-processing, within MiXCR the basic workflow
starts with alignment, where sequencing reads are aligned to spliced reference V, D,
J, and C genes of T or B cell receptors. After that there is a partial assembly step
whereby overlapping sequencing reads (which are expected in nontargeted or
RNA-sequencing reads) are joined into sufficiently long CDR3-containing contigs
for downstream analysis. We set the minimal overlap to be five base pairs and the
length of the kmer taken from the VJ junction for overlap search to be 12 base
pairs. We also go through a procedure of extension for imputation of higher quality
germline sequences from well-trimmed TCR sequencing reads. To quantify VDJ
expression per sample, only reads that supported these CDR3 contigs were counted
and then subsequently normalized by the total library size of that RNA-seq
sequencing run, as are the relative number of reads supporting each distinct CDR3
contig sequence assembled.
HBV expression, integration, and antigen binding affinity. Raw RNA-
sequencing reads that did not map to the GRCh38 reference genome was assem-
bled into contigs using Trinity (using –no_run_chrysalis –no_run_butterfly flags,
which effectively only invokes Inchworm) to perform greedy kmer-21 contig
assembly. Contigs with a sufficiently high entropy (to exclude homopolymer
sequences), at least 100 bp long and supported by at least 20 reads were retained for
further analysis. Contigs were BLASTed (BLAST version 2.2.26+ 57) to HBV
sequence58 and all contigs with bitscore >= 100 were retained. Contig expression
was computed using the RPKM summary statistic defined by the number of reads
per contig scaled by the product of the total number of unmapped reads for that
sample and the contig length. The viral antigen burden and predicted immune
binding affinity of HLA/antigen ligand pairs were estimated using the following
procedure. First we selected the BLAST contig mappings that maximized the bit-
score, a logarithmically rescaled version of the contig raw alignment score that is
independent of the size of the search space, for each sample. This defined which
reference HBV genome was ‘expressed’ in that sample. We then took that specific
HBV genome in its entirety and first computed the longest open reading frames
using TransDecoder.LongOrfs and then predicted likely coding regions (CDS)
using TransDecoder.Predict59 at default settings. Importantly, this means that all
ORFs shorter than 300 aa are excised. Aggregating all of the final candidate ORF
regions for each sample-specific HBV genome, we fragmented each into over-
lapping fragments ranging from 9 to 12 aa in length and computed the class I HLA
binding affinity using NetMHCCons20 for each fragment-patient class I allele
combination. Viral integration sites were found by computing putative fusion
transcripts between a faux 25th chromosome and the regional bitscore-maximizing
HBV genome strain as above. Briefly, we examined the chimeric alignments from
the initial regional STAR alignments and post-filtered them with an emphasis on
precision using STARChip (version 1.1)60.
Regional expression variance. To account for regional gene expression changes,
we carried out statistical tests for differential expression across all combinations of
regions within a given patient by testing the null hypothesis that the logarithmic
fold change (LFC) between regions for a given gene’s expression is zero. For
patients with three or more regional samples, we compared all unique regional
combinations building from 2 × 1 comparisons. In order to facilitate gene ranking,
stable effect size estimation, and variance sharing across genes among samples we
used DESeq261 to model the dependence of the dispersion of the count data on the
average expression strength overall of the samples in the comparison. Since all
comparisons were between samples on the same genetic background, tissue type,
and sequencing run, we simply imposed a more stringent false discovery rate
(FDR) of 1% to account for the inherent lack of power of these statistical tests.
Gene Set Enrichment Analysis (GSEA)62 was used to determine if a gene list
composed of expressed CTAs26 shows cumulative changes in expression across our
ITH dataset. We performed pre-ranked GSEA using the java implementation
downloaded from the Broad Institute webpage. Genes were ranked by differential
expression between tumor and adjacent samples (determined separately for each
patient). Enrichment scores were determined from a running sum statistic, when
the statistic is at the maximum deviation from zero.
Analyses on the TCGA. Mutation Annotation Files (MAF) and RNA-Seq FASTQs
for the TCGA dataset (LIHC cohort) were downloaded from the National Cancer
Institute’s GDC Data Portal (https://portal.gdc.cancer.gov/) for HCC patients.
Matched clinical data were downloaded from the cBioPortal (http://www.
cbioportal.org/). RNA-Seq data were aligned to hg38 with STAR (v2.5.1b) in two-
pass mode. Gene counts for Gencode v23 (www.gencodegenes.org) gene annota-
tions were generated using featureCounts. Read counts underwent TMM nor-
malization and logCPM transformation using voom63.
Single-cell RNA-seq. Tissue was collected in 5 ml of RPMI media. Further dis-
aggregation of tissue into a single-cell solution for sequencing was completed using
the MACs tumor dissociation kit with the standard tough tumor protocol. Briefly,
the MACs tumor dissociation kit enzyme mix (300 μl) was added to each sample.
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Next, samples were put into the gentleMACs Dissociator and ran through the
tough tumor program. The cell suspension was then applied to a 70 um cell
strainer. Cells were pelleted and resuspended in PBS. Next, the suspension was
treated with red blood cell lysis solution for 10 min, diluted in PBS, pelleted and
resuspended in 3 ml PBS. Cells were diluted 1:2 in trypan blue prior to counting.
The resulting single-cell suspension was diluted to a concentration of 1000 live
cells/μl from which 10 μl was used as input for the ChromiumTM Single Cell 3’
Protocol as the following describes.
The single-cell chip loading, GEM generation & barcoding, post GEM-RT &
cDNA amplification, and library construction were performed according to the
ChromiumTM Single Cell 3’ Protocol - Chemistry v2. For GEM generation an input
of 10,000 cells total, at 1000 cells/μl density, was targeted for each sample, with a
target cell recovery of 6000 cells. Library construction, enzymatic fragmentation,
End-repair and A-tailing were performed as follows: pre-cool block at 4 °C hold,
fragmentation at 32 °C for 5 min; End repair and A-tailing 65 °C for 30 min and
held at 4 °C. Post reaction cleanup was performed, followed by adaptor ligation.
Adaptor ligation incubation was done at 20 °C for 15 min. Post adaptor ligation
cleanup was then performed, followed by sample index PCR with the following
parameters: 98 °C for 45 sec; followed by 14 cycles: 98 °C for 20 sec; 54 °C for
30 sec; and 72 °C for 20 sec; followed by 72 °C for 1 min and held at 4 °C.
Quantification of the constructed libraries was evaluated using Qubit dsDNA HS
Assay Kit (Thermo Fisher), Agilent cDNA High Sensitivity Kit, and Kapa DNA
Quantification Kit for Illumina platforms, following the manufacturer’s
instructions. Generated libraries were sequenced on the Illumina HiSeq2500, using
the paired-end 2 × 125 bp sequencing protocol. Sequencing run parameters were
setup according to version 2 chemistry, the number of cycles for each read as
follows: Read 1: 26 cycles, i7 index: 8 cycles, i5 index: 0 cycles and Read 2: 98 cycles.
An analysis of the single-cell RNA-seq data was done with the package Seurat
(version 2.1)64. Initial filtering steps removed all the cells with fewer than 200 genes
or a percentage of mitochondrial reads higher than the third quartile in our
samples. Reads were normalized, scaled and adjusted for total amount of
expression (nUMI) and the percentage of mitochondrial reads using linear
regression. Next we computed and clustered the cells with a graph-based algorithm
for modularity optimization using the 10 principal components of the normalized
expression matrix, computing marker genes for each cluster65. Malignant
hepatocytes were defined using a reported gene signature derived from human
HCC single cells66. We also applied nonlinear dimensionality reduction techniques
like t-SNE67 and topological data analysis (TDA, Ayasdi Platform). Prediction for
the molecular classes S1-S333 at the single-cell level was done using permutation
tests68.
We used the SCENIC workflow (version 1.0)34, which consists of three steps.
First, TF-directed coexpression networks are learned from the batch corrected,
variance stabilized, single-cell RNA expression data using the random forest based
approach GENIE3, which allows for nonlinear gene-gene contributions to a
particular TF association. To filter these TF- coexpression modules, each was
subjected to a cis-regulatory motif analysis using RcisTarget (SCENIC) and only
modules with a highly significant motif enrichment (P < 0.01) were retained for
further analysis and pruned of indirect targets lacking motif enrichment. These
filtered TF-coexpression module pairs, called regulons, were then projected onto
the ranks of expressed genes for each cell and compared using the AUCell routine
(SCENIC). AUCell uses a cumulative criterion to determine if a critical subset of
the regulon gene set is enriched at the top percentile of expression in each cell. Our
results do not depend greatly on any reasonable choice of this threshold.
Survival analysis. We used Kaplan-Meier curves and log-rank test to evaluate the
impact of mutation load, number of tumor clones and the ITH signature on
patient’s outcome in the TCGA dataset. We first conducted differential gene
expression between all tumor regions in those patients with at least three regions
sampled. The p-values for this analysis were computed from the standard para-
metric differential expression test assuming a negative binomial count distribution
(DESeq261), adjusted by the Benjamini-Hochberg procedure. Using these genes, we
created a PCA plot and used the first five principal components (i.e., eigenvectors
of covariance matrix) to evaluate their prognostic impact in the TCGA-HCC
dataset. We computed the integrated Brier Score to evaluate the prognostic impact
of each of these gene sets69, employing nested-cross validation to simultaneously
learn ITH signatures and estimate extra-sample (generalization) error (as shown in
Supplementary Fig. 8). Explicitly, we carried out the following procedure:
(1) Randomly divide the LIHC HCC subset of TCGA data into K= 3 folds with
approximately equal numbers of survival events.
(2) Outer loop: For each ki within the λK folds we performed:
a. Set Ki-fold as the test set.
b. Perform an elastic-net penalized regression with the set of all
intratumoral gene expression differences (called gene expression
gradients) in tumors with at least three regions sampled tested as ITH
hyperparameters (I), which acts as an automated hyperparameter
learning, on the remaining K− 1 folds.
c. For a given specific learned gene expression gradient in I
i. Inner loop: For each K_j in remaining K− 1 folds:
1. Set fold Kj as validation set
2. Train new elastic-net on remaining K -2 folds using leave-one-out
cross-validation to obtain overall penalization factor λ* (λ*(1− α)
*L2 penalty+ α*L1 penalty)), 0 <= α <= 1, λ >= 0
3. Evaluate model performance on fold Kj, extracting putatively
optimal (minimal) and parsimonious (1se) λ
ii. Calculate average performance of ITH parameter setting I over K -
2 folds
d. Train model that had optimal-performing gene expression gradient I
from inner loop over K− 1 folds
e. Evaluate performance via K= 10 cross-validation on fold Ki by
computing Lebesgue integrals over discontinuous Brier scores to find
Integrated Brier Score (IBS)
(3) Average IBS-scores (performance) of test models over all K folds.
(4) Report averaged IBS score and compare to .632+ bootstrap-resampling
estimate previously obtained.
We then repeated the whole nested-cross-validation (nested-cv) procedure,
steps 1–4, over a range of penalty-mixing α-choices ((ridge-like) 0.1 < α < 1 (lasso))
in elastic-net in order to hedge against an arbitrary or self-serving choice of α. In
other words, we also averaged the entire nested-cv procedure over α. We used a
procedure of variance ranking30 to select the minimum number of genes required
to retain the predictive power of the ITH signature. We selected the genes identified
in the top 5% by this procedure, which resulted in 363 genes (i.e., 140 upregulated
in H2.a vs the other regions of patients 2 and 223 downregulated in H2.a vs the
other regions). We used the Nearest Template Prediction method70 to determine
which patients in the TCGA-HCC dataset had a significant enrichment of the ITH
signatures. To control for optimism71, we computed the model discrimination
indices for the ITH signature as well as other known prognostic signatures in
HCC31. Using the learned ITH signatures we controlled for multiple testing and
random patient effects by performing repeated cross-validation to explicitly
compute the discrimination indices for ITH and other models (see Supplementary
Fig. 8). These analyses, principally nested-cross validation, ensured that neither a
random patient nor gene selection effect account for the prediction accuracy of our
ITH signature. We conducted multivariate analyses using Cox regression modeling
including the ITH signature and other potential correlates of cancer evolution such
as DNA-based tumor clonality or mutational burden. We also used our TCGA
derived Bayesian gene regulatory network to score the potential deleterious
downstream impact of mutations. We intersected each patient’s mutational
signature on the network and computed the statistics of nodal and global, averaged
topological quantities such as out degree, neighborhood connectivity, and
clustering (GSE63898) coefficient72 (Supplementary Table 7). The prognostic
performance of the ITH signature was also tested in the Heptromic dataset,
consisting of 228 HCC patients treated with resection for which whole-
transcriptome data are already available73.
Reporting summary. Further information on research design is available in
the Nature Research Reporting Summary linked to this article.
Data availability
Sequence data (i.e., RNA-seq, scRNAseq, DNA targeted, exome sequencing) and
genotyping arrays are publicly available through accession numbers: E-MTAB-5905
(source data underlying Figs. 1c, 2a, b, 3a, b, 3d, 4a–c and Supplementary Figs. 2b–c,
3a, b, 4, 5, 7, 8a, b) GSE112271 (source data underlying Figs. 6a, b, 7a, b and
Supplementary Fig. 9), E-MTAB-5899 (source data underlying Supplementary Fig. 3c),
E-MTAB-8127 (source data underlying Supplementary Fig. 6), E-MTAB-5878 (source
data underlying Figs. 1b, 3c), https://clients.adaptivebiotech.com (source data underlying
Fig. 2c). RNA-seq and SNP array from patient 5 are not deposited due to lack of patient-
specific deposition consent. Mutation Annotation Files (MAF) and RNA-Seq FASTQs
for the TCGA dataset (LIHC cohort) were downloaded from the National Cancer
Institute’s GDC Data Portal (https://portal.gdc.cancer.gov/) for HCC patients (source
data underlying Fig. 5a–d and Supplementary Fig. 8a–c). The Heptromic Cohort
expression array data has previously been deposited at gene expression omnibus
(GSE63898, source data underlying Supplementary Fig. 8d, e).
Code availability
Custom R code for the analyses included in the study can be obtained by contacting
directly Dr. Losic (bojan.losic@mssm.edu).
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